

## Publication List Priv.-Doz. Dr. Mazda Adli (September 22, 2017)

### Content:

- A. Original Papers (First or Senior Authorships)
- B. Co-Authorships
- C. Case Reports
- D. Reviews
- E. Comments
- F. Other Publications (not peer-reviewed)
- G. Editor
- H. Book Chapters

### A. Major And Original Papers (First or Senior Authorships):

1.	Ricken R, Bopp S, Schlattmann P, Himmerich H, Bschor T, Richter C, Elstner S, Stamm TJ, Schulz-Ratei B, Lingesleben A, Reischies FM, Sterzer P, Borgwardt S, Bauer M, Heinz A, Hellweg R, Lang UE, <u>Adli M</u> (2017). Ghrelin Serum Concentrations Are Associated with Treatment Response During Lithium Augmentation of Antidepressants. <i>Int J Neuropsychopharmacol.</i> 20(9):692-697.	IMPACT FACTOR 4.712
2.	<u>Adli M</u> , Wiethoff K, Baghai TC, Fisher R, Seemüller F, Laakmann G, Brieger P, Cordes J, Malevani J, Laux G, Hauth I, Möller HJ, Kronmüller KT, Smolka MN, Schlattmann P, Berger M, Ricken R, Stamm TJ, Heinz A, Bauer M (2017). How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial. <i>Int J Neuropsychopharmacol.</i> 20(9):721-730.	IMPACT FACTOR 4.712
3.	<u>Adli M</u> , Berger M, Brakemeier EL, Engel L, Fingerhut J, Gomez-Carrillo A, Hehl R, Heinz A, H JM, Mehran N, Tolaas S, Walter H, Weiland U, Stollmann J (2017). Neurourbanism: towards a new discipline. <i>Lancet Psychiatry.</i> 4(3):183-185.	IMPACT FACTOR 11.588
4.	Ricken R, Bopp S, Schlattmann P, Himmerich H, Bschor T, Richter C, Stamm TJ, Bauer F, Heinz A, Hellweg R, Lang UE, <u>Adli M</u> (2016). Leptin serum concentrations are associated with weight gain during lithium augmentation. <i>Psychoneuroendocrinology.</i> 71:31-35.	IMPACT FACTOR 4.944
5.	Stamm TJ, Rampp C, Wiethoff K, Stingl J, Mössner R, O Malley G, Ricken R, Seemüller F, Keck M, Fisher R, Gaebel W, Maier W, Möller HJ, Bauer M, <u>Adli M</u> (2016). The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression. <i>J Psychopharmacol.</i> 30(1):40-7.	IMPACT FACTOR 3.898
6.	<u>Adli M</u> , Berger M (2015). Tricyclic antidepressants for initial treatment of depressive episodes? <i>Con. Nervenarzt.</i> [Epub ahead of print]	IMPACT FACTOR 0.787
7.	Köhler S, Wiethoff K, Ricken R, Stamm T, Baghai TC, Fisher R, Seemüller F, Brieger P, Cordes J, Malevani J, Laux G, Hauth I, Möller HJ, Zeiler J, Heinz A, Bauer M, <u>Adli M</u> (2015). Characteristics and differences in treatment outcome of inpatients with chronic vs. episodic major depressive disorders. <i>J Affect Disord.</i> 173: 126-33.	IMPACT FACTOR 3.71
8.	<u>Adli M</u> , Hegerl U. (2014). Do we underestimate the benefits of antidepressant drugs? <i>Lancet.</i> 383(9926): 1361-2.	IMPACT FACTOR 39.207
9.	Stamm TJ, Becker D, Sondergeld LM, Wiethoff K, Hiemke C, O'Malley G, Ricken R, Bauer M, <u>Adli M</u> (2014). Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring. <i>Pharmacopsychiatry.</i> 47(4-5): 174-9.	IMPACT FACTOR 2.168
10.	Fakhri H*, Ricken R*, <u>Adli M*</u> , Fajol A, Walter M, Föller M, Lang F, Lang UE,	IMPACT

	Lange C (2014). Impact of Lithium Treatment on FGF-23 Serum Concentrations in Depressive Patients. <i>J Clin Psychopharmacol.</i> 34(6): 745-7.	FACTOR 3.761
11.	Stamm TJ, Stingl J, Wiethoff K, Ricken R, Heinz A, Bauer M, O'Malley G, Adli M (2013). Depression with psychotic features is influenced by the polymorphism of the serotonin transporter gene. <i>J Affect Disord.</i> 151: 605-610.	IMPACT FACTOR 3.383
12.	Ricken R*, Adli M*, Lange C, Krusche E, Stamm TJ, Gaus S, Koehler S, Nase S, Bschor T, Richter C, Steinacher B, Heinz A, Rapp MA, Borgwardt S, Hellweg R, Lang UE (2013). Brain-derived neurotrophic factor serum concentrations in acute depressive patients increase during lithium augmentation of antidepressants. <i>J Clin Psychopharmacol.</i> 33(6): 806-9.	IMPACT FACTOR 3.761
13.	Lange C, Zschucke E, Ising M, Uhr M, Bempohl F, <u>Adli M</u> (2013). Evidence for a normal HPA axis response to psychosocial stress in patients remitted from depression. <i>Psychoneuroendocrinology</i> , 38(11): 2729-36.	IMPACT FACTOR 5.591
14.	Kiermeir J, Gassner LM, Siebörger A, Wiethoff K, Ricken R, Stamm T, Bauer M, Heinz A, <u>Adli M</u> (2012). Euthymic Therapy to Reduce Residual Symptoms of Depression and Strengthen Self-Care: a Randomised Controlled Trial. <i>German J Psychiatry.</i> 15 (1): 15-22	
15.	<u>Adli M</u> , Kleinert S, Bonk M, Wesslingh S, Ganten D (2011). From science to policy: the M8 Alliance invites policy makers to step in. <i>Lancet</i> , 378: 1447-1449	IMPACT FACTOR 30.758
16.	Ricken R, Wiethoff K, Reinhold T, Schietsch K, Stamm T, Kiermeir J, Neu P, Heinz A, Bauer M, <u>Adli M</u> (2011). Algorithm-guided treatment of depression reduces treatment costs - Results from the randomized controlled German Algorithm Project (GAPII). <i>J Affect Disord.</i> 134:249-256	IMPACT FACTOR 3.740
17.	Sterzer P, Hilgenfeldt T, Freudenberg P, <u>Adli M</u> (2011). Unconscious emotional information processing in patients with major depressive disorder. <i>Psychol Med</i> 5: 1-10	IMPACT FACTOR 5.012
18.	Wiethoff K, Bauer M, Baghai TC, Möller HJ, Fisher R, Hollinde D, Kiermeir J, Hauth I, Laux G, Cordes J, Marneros A, Kronmüller K, Zeiler J, <u>Adli M</u> (2010). Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project. <i>J Clin Psychiatry</i> 71:1047-54	IMPACT FACTOR 5.218
19.	<u>Adli M</u> , Bschor T, Bauer M, Lucka C, Lewitzka U, Ising M, Uhr M, Müller-Oerlinghausen B, Baethge C (2009). Long-term outcome after lithium augmentation in unipolar depression: focus on HPA system activity. <i>Neuropsychobiology</i> 60: 23-30.	IMPACT FACTOR 1.752
20.	<u>Adli M</u> , Kleinert S, Lafont, A, Kahn A, Ganten D (2009). Shaping the future of health care: the Berlin 2009 Evolution of Medicine Summit. <i>Lancet</i> 373: 519-520	IMPACT FACTOR 30.758
21.	Bauer M, Pfennig A, Linden M, Smolka M, Neu P, <u>Adli M</u> (2009). Efficacy of an algorithm-guided treatment compared to treatment as usual: A randomized controlled study of inpatients with depression. <i>J Clin Psychopharmacology</i> 29: 327-333.	IMPACT FACTOR 5,092
22.	Bauer M, Glenn T, Whybrow PC, Grof P, Rasgon N, Alda M, Marsh W, Sagduyu K, Schmid R, <u>Adli M</u> (2008). Changes in self-reported sleep duration predict mood changes in bipolar disorder. <i>Psychol Med.</i> 38: 1069-71.	IMPACT FACTOR 4.718
23.	<u>Adli M</u> , Wiethoff K, Pfennig A, Stamm T, Baethge C, Bauer M (2008).	IMPACT

	Olanzapine in the treatment of depression with psychotic features – a prospective open-label study. <i>Int J Psychiatr Clin Practice</i> 12: 202-209.	FACTOR 0.410
24.	Mahlberg R, <u>Adli M</u> , Bschor T, Kienast T (2008). Age effects on trail making test during acute depressive and manic episode. <i>Int J Neurosci</i> . 118: 1347-1356.	IMPACT FACTOR 0.884
25.	Mahlberg R, Kienast T, Bschor T, <u>Adli M</u> (2008). Evaluation of time memory in acutely depressed patients, manic patients, and healthy controls using a time reproduction task. <i>Eur Psychiatry</i> 23: 430-433.	IMPACT FACTOR 2.433
26.	<u>Adli M</u> , Pilhatsch M, Bauer M, Köberle U, Ricken R, Janssen G, Ulrich S, Bschor T (2008). Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. <i>Pharmacopsychiatry</i> 41: 252-7.	IMPACT FACTOR 2.402
27.	<u>Adli M</u> , Hollinde D, Stamm T, Wiethoff K, Tsahuridu M, Kirchheiner J, Heinz A, Bauer M (2007). Response to lithium augmentation treatment in depression is associated with the glycogen synthase kinase 3-beta (GSK3-beta) - 50T/C single nucleotide polymorphism. <i>Biol Psychiatry</i> 62: 1295-1302	IMPACT FACTOR 8.672
28.	<u>Adli M</u> , Whybrow P, Grof P, Rasgon N, Gyulai L, Baethge C, Glenn T, Bauer M (2005). Use of polypharmacy and self-reported mood in outpatients with bipolar disorder. <i>Int J Psychiatry Clin Practice</i> 9: 251-256	IMPACT FACTOR 0.410
29.	<u>Adli M</u> , Baethge C, Langlitz N, Bauer M (2005). Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed ? – a systematic review. <i>Eur Arch Psychiatry Clin Neurosci</i> . 255: 387-400	IMPACT FACTOR 2.852
30.	<u>Adli M</u> , Berghöfer A, Linden M, Helmchen H, Müller-Oerlinghausen B, Mackert A, Stamm T, Bauer M (2002). Effectiveness and feasibility of a standardized stepwise drug treatment algorithm for inpatients with depressive disorders – results of a two-year observational study. <i>J Clin Psychiatry</i> 63: 782-79	IMPACT FACTOR 5.053

## **B. Co-Authorships:**

31.	Haffner P, Quinlivan E, Fiebig J, Sondergeld LM, Strasser ES, <u>Adli M</u> , Moritz S, Stamm TJ (2017). Improving functional outcome in bipolar disorder: A pilot study on metacognitive training. <i>Clin Psychol Psychother</i> . [Epub ahead of print].	IMPACT FACTOR 1.933
32.	Holzinger F, Fahrenkrog S, Roll S, Kleefeld F, <u>Adli M</u> , Heintze C (2017). Discharge management strategies and post-discharge care interventions for depression - Systematic review and meta-analysis. <i>J Affect Disord</i> . 223:82-94.	IMPACT FACTOR 3.845
33.	Gruebner O, Rapp MA, <u>Adli M</u> , Kluge U, Galea S, Heinz A (2017). Cities and Mental Health. <i>Dtsch Arztebl Int</i> . 114(8):121-127.	IMPACT FACTOR 3.738
34.	Spellmann I, Schennach R, Seemüller F, Meyer S, Musil R, Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Bauer M, <u>Adli M</u> , Zeiler J, Bender W, Kronmüller KT, Ising M, Brieger P, Maier W, Lemke MR, Rütger E, Klingberg S, Gastpar M, Riedel M, Möller HJ (2016). Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-	IMPACT FACTOR 4.113

	year follow-up naturalistic studies. <i>Eur Arch Psychiatry Clin Neurosci.</i> 267(4):303-313.	
35.	Strasser ES, Haffner P, Fiebig J, Quinlivan E, <u>Adli M</u> , Stamm TJ (2016). Behavioral measures and self-report of impulsivity in bipolar disorder: no association between Stroop test and Barratt Impulsiveness Scale. <i>Int J Bipolar Disord.</i> 4(1):16.	IMPACT FACTOR 4.88
36.	The International Consortium on Lithium Genetics (ConLiGen). Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. <i>Hum Mol Genet</i> 2016 Jun 21. [Epub ahead of print]	IMPACT FACTOR 5.985
37.	Seemüller F, Obermeier M, Schennach R, Bauer M, <u>Adli M</u> , Brieger P, Laux G, Riedel M, Falkai P, Möller HJ (2016). Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients. <i>BMC Psychiatry.</i> 2016 May 20;16:153.	IMPACT FACTOR 2.210
38.	Hasselmann H, Bellmann-Strobl J, Ricken R, Oberwahrenbrock T, Rose M, Otte C, <u>Adli M</u> , Paul F, Brandt AU, Finke C, Gold SM (2016). Characterizing the phenotype of multiple sclerosis – associated depression in comparison with idiopathic major depression. <i>Multiple Sclerosis Journal.</i> <i>Mult Scler.</i> 2016 Jan 8. pii: 1352458515622826. [Epub ahead of print]	IMPACT FACTOR 4.82
39.	The International Consortium on Lithium Genetics (ConLiGen). Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. <i>Lancet.</i> 2016 Mar 12;387(10023):1085-93.	IMPACT FACTOR 39.207
40.	Borgmann M, Holtkamp M, <u>Adli M</u> , Behr J (2015). Depression and epilepsy: Two clinical pictures with common causes? <i>Nervenarzt.</i> [Epub ahead of print]	IMPACT FACTOR 0.787
41.	Bauer M, Berman S, Stamm T, Plotkin M, <u>Adli M</u> , Pilhatsch M, London ED, Helleman GS, Whybrow PC, Schlagenhaut F (2015). Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study. <i>Mol Psychiatry.</i> <i>Mol Psychiatry.</i> 2016 Feb;21(2):229-36.	IMPACT FACTOR 5.620
42.	Berger M, <u>Adli M</u> , Beine KH, Bschor T, Herpertz S, Lauterbach K (2015). Psychiatrische Versorgung: Das Krankenhaus-Psych-Budget – ein Alternativkonzept. <i>Dtsch Arztebl</i> 2015; 112(13): A-574 / B-488 / C-476	IMPACT FACTOR 3,608
43.	Willert A, Mohnke S, Erk S, Schnell K, Romanczuk-Seiferth N, Krusche E, Schreier S, Spengler S, Herold D, Wackerhagen C, Pöhland L, Garbusow M, Stamm T, <u>Adli M</u> , Heinz A, BERPohl F, Walter H. (2015). Alterations in neural Theory of Mind processing in euthymic patients with bipolar disorder and unaffected relatives. <i>Bipolar Disorders.</i> 17(8):880-91	IMPACT FACTOR 4.888
44.	Fakhri H, Ricken R, <u>Adli M</u> , Fajol A, Walter M, Föller M, Lang F, Lang UE, Lange C (2014). Impact of Lithium Treatment on FGF-23 Serum Concentrations in Depressive Patients. <i>J Clin Psychopharmacol.</i> 34(6): 745-7.	IMPACT FACTOR 3.761
45.	Bauer M, <u>Adli M</u> , Ricken R, Severus E, Pilhatsch M (2014). Role of lithium augmentation in the management of major depressive disorder. <i>CNS Drugs.</i> 28(4): 331-42.	IMPACT FACTOR 4.376
46.	Seemüller F, Meier S, Obermeier M, Musil R, Bauer M, <u>Adli M</u> , Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Riedel M, Falkai P, Möller HJ (2014). Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. <i>Eur Arch Psychiatry Clin Neurosci.</i> 264(7): 567-75.	IMPACT FACTOR 3.355
47.	Stamm TJ, Lewitzka U, Sauer C, Pilhatsch M, Smolka MN, Koeberle U, <u>Adli M</u> , Ricken R, Scherk H, Frye MA, Juckel G, Assion HJ, Gitlin M, Whybrow PC, Bauer M (2014). Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-	IMPACT FACTOR 3.761

	controlled study. <i>J Clin Psychiatry</i> . 75(2): 162-8.	
48.	Rentzsch J, <u>Adli M</u> , Wiethoff K, Gómez-Carrillo de Castro A, Gallinat J (2014). Pretreatment anterior cingulate activity predicts antidepressant treatment response in major depressive episodes. <i>Eur Arch Psychiatry Clin Neurosci</i> . 264(3): 213-23.	IMPACT FACTOR 3.525
49.	Manchia M, <u>Adli M</u> , Akula N, Ardau R, Aubry JM, Backlund L, Banzato CE, Baune BT, Bellivier F, Bengesser S, Biernacka JM, Brichant-Petitjean C, Bui E, Calkin CV, Cheng AT, Chillotti C, Cichon S, Clark S, Czerski PM, Dantas C, Zompo MD, Depaulo JR, Detera-Wadleigh SD, Etain B, Falkai P, Frisé L, Frye MA, Fullerton J, Gard S, Garnham J, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Heilbronner U, Hoban R, Hou L, Jamain S, Kahn JP, Kassem L, Kato T, Kelsoe JR, Kittel-Schneider S, Kliwicky S, Kuo PH, Kusumi I, Laje G, Lavebratt C, Leboyer M, Leckband SG, López Jaramillo CA, Maj M, Malafosse A, Martinsson L, Masui T, Mitchell PB, Mondimore F, Monteleone P, Nallet A, Neuner M, Novák T, O'Donovan C, Osby U, Ozaki N, Perlis RH, Pfennig A, Potash JB, Reich-Erkelenz D, Reif A, Reininghaus E, Richardson S, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schubert OK, Schweizer B, Seemüller F, Grigoriou-Serbanescu M, Severino G, Seymour LR, Slaney C, Smoller JW, Squassina A, Stamm T, Steele J, Stopkova P, Tighe SK, Tortorella A, Turecki G, Wray NR, Wright A, Zandi PP, Zilles D, Bauer M, Rietschel M, McMahon FJ, Schulze TG, Alda M (2013). Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. <i>PLoS One</i> . 8(6):e65636	IMPACT FACTOR 3.530
50.	Berghöfer A, Alda M, <u>Adli M</u> , Baethge C, Bauer M, Bschor T, Grof P, Müller-Oerlinghausen B, Rybakowski JK, Suwalska A, Pfennig A. Stability of lithium treatment in bipolar disorder - long-term follow-up of 346 patients. <i>Int J Bipolar Disord</i> . 2013 Jul 31;1:11.	
51.	Rhein C, Naumann J, Mühle C, Zill P, <u>Adli M</u> , Hegerl U, Hiemke C, Mergl R, Möller HJ, Reichel M, Kornhuber J (2013). The Acid Sphingomyelinase Sequence Variant p.A487V Is Not Associated With Decreased Levels of Enzymatic Activity. <i>JIMD Rep</i> . 8:1-6	IMPACT FACTOR 4.138
52.	Musil R, Zill P, Seemüller F, Bondy B, Meyer S, Spellmann I, Bender W, <u>Adli M</u> , Heuser I, Fisher R, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller HJ, Riedel M (2013). Genetics of emergent suicidality during antidepressive treatment--data from a naturalistic study on a large sample of inpatients with a major depressive episode. <i>Eur Neuropsychopharmacol</i> . 23(7): 663-74.	IMPACT FACTOR 4.736
53.	Musil R, Zill P, Seemüller F, Bondy B, Obermeier M, Spellmann I, Bender W, Adli M, Heuser I, Zeiler J, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller HJ, Riedel M (2013). No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. <i>Eur Arch Psychiatry Clin Neurosci</i> . 263(5):405-12.	IMPACT FACTOR 3.355
54.	Lange C, <u>Adli M</u> , Zschucke E, Beyer R, Ising M, Uhr M, BERPohl F (2012). Affective set-shifting deficits in patients with major depression in remission. <i>J Psychiatr Res</i> . 46(12):1623-6.	IMPACT FACTOR 4.460
55.	Stoy M, Schlagenhaut F, Sterzer P, BERPohl F, Hägele C, Suchotzki K, Schmack K, Wrase J, Ricken R, Knutson B, Adli M, Bauer M, Heinz A, Ströhle A (2012). Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram. <i>J Psychopharmacol</i> . 26:677-688.	IMPACT FACTOR 3.396
56.	Ricken R, BERPohl F, Schlattmann P, Bschor T, Adli M, Mönter N, Bauer M (2012). Long-term treatment with supraphysiological doses of thyroid hormone in affective disorders - effects on bone mineral density. <i>J Affect Disord</i> . 136: 89-94.	IMPACT FACTOR 3.740

57.	Riedel M, Möller HJ, Obermeier M, Adli M, Bauer M, Kronmüller K, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Henkel V, Seemüller F (2011). Clinical predictors of response and remission in inpatients with depressive syndromes. <i>J Affect Disord.</i> 133:137-49.	IMPACT FACTOR 3.383
58.	Seemüller F, Riedel M, Obermeier M, Schennach-Wolff R, Spellmann I, Meyer S, Bauer M, Adli M, Kronmüller K, Ising M, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Möller HJ (2011). The validity of self-rated psychotic symptoms in depressed inpatients. <i>Eur Psychiatry.</i> Mar 8. [Epub ahead of print]	IMPACT FACTOR 3.08
59.	Henkel V, Seemüller F, Obermeier M, <u>Adli M</u> , Bauer M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Riedel M, Möller HJ (2010). Relationship between baseline severity and antidepressant treatment outcome. <i>Pharmacopsychiatry</i> Oct 27 2010 [Epub ahead of print]	IMPACT FACTOR 2.317
60.	Riedel M, Möller HJ, Obermeier M, Schennach-Wolff R, Bauer M, <u>Adli M</u> , Kronmüller K, Nickel T, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Seemüller F (2010). Response and remission criteria in major depression – a validation of current practice. <i>J Psychiatr Res</i> 44: 1063-1068	IMPACT FACTOR 4.679
61.	Seemüller F, Möller HJ, Obermeier M, <u>Adli M</u> , Bauer M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Henkel V, Riedel M (2010). Do efficacy and effectiveness samples differ in antidepressant treatment outcome? an analysis of eligibility criteria in randomized controlled trials. <i>J Clin Psychiatry</i> 71:1425-33	IMPACT FACTOR 5.218
62.	Bauer M, <u>Adli M</u> , Bschor T, Pilhatsch M, Pfennig A, Sasse J, Lewitzka U (2010). Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. <i>Neuropsychobiology</i> 62: 36-42	IMPACT FACTOR 1.752
63.	Schulze G, Alda M, <u>Adli M</u> , Akula N, Ardaur R, Chilotti C, Cichon S, Czerski P, Del Zompo M, Detera-Wadleigh S, Grof P, Gruber O, Hashimoto R, Hauser J, Hoban R, Iwata N, Kassem L, Kato T, Kittel-Schneider S, Kliwicki S, Kelsoe J, Kusumi I, Laje G, Leckband S, Manchia M, MacQueen G, Masui T, Ozaki N, Perlis R, Pfennig A, Piccardi P, Richardson S, Rouleau G, reif A, Rybakowski J, Sasse J, Schumacher J, Severino G, Smoller J, Squassina A, Turecki G, Young L, Yoshikawa T, Bauer M, MacMahon F (2010). The international Consortium on Lithium Genetics (ConLiGen) – an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. <i>Neuropsychobiology</i> 62: 72-78	IMPACT FACTOR 1.752
64.	Mazurek B, Olze H, Haupt H, Klapp BF, <u>Adli M</u> , Gross J, Szczepek AJ. (2010). Molekularbiologische Aspekte der Neuroplastizität: Ansätze für die Therapie bei Tinnitus und Hörstörungen. <i>HNO</i> , 58, 973-982	IMPACT FACTOR 1.752
65.	Mazurek B, Stöver T, Haupt H, Klapp BF, <u>Adli M</u> , Gross J, Szczepek AJ (2010). The significance of stress: its role in the auditory system and the pathogenesis of tinnitus. <i>HNO</i> 58(2):162-72	IMPACT FACTOR 0.570
66.	Seemüller F, Riedel M, Obermeier M, Bauer M, <u>Adli M</u> , Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Dichgans E, Bottländer R, Musil R, Möller HJ (2010). Outcomes of 1014 naturalistically treated inpatients with major depressive episode. <i>Eur Neuropsychopharmacol</i> 20 :346-55.	IMPACT FACTOR 3.661
67.	Bermpohl F, Kahnt T, Dalanay U, Hägele C, Sajonz B, Wegner T, Stoy M, <u>Adli M</u> , Krüger S, Wrase J, Ströhle A, Bauer M, Heinz A (2010). Altered representation of expected value in the orbitofrontal cortex in mania. <i>Hum Brain Mapp</i> 31: 958-69	IMPACT FACTOR 5.395

68.	Abou Jamra R, Schulze TG, Becker T, Brockschmidt FF, Green E, Alblas MA, Wendland JR, <u>Adli M</u> , Grozeva D, Strohmeier J, Georgi A, Craddock N, Propping P, Rietschel M, Nöthen MM, Cichon S, Schumacher J (2010). A systematic association mapping on chromosome 6q in bipolar affective disorder-evidence for the melanin-concentrating-hormone-receptor-2 gene as a risk factor for bipolar affective disorder. <i>Am J Med Genet B Neuropsychiatr Genet</i> 153B: 878-84	IMPACT FACTOR 3.932
69.	Berpohl F, Walter M, Sajonz B, Lücke C, Hägele C, Sterzer P, <u>Adli M</u> , Heinz A, Northoff G (2009). Attentional modulation of emotional stimulus processing in patients with major depression—Alterations in prefrontal cortical regions. <i>Neuroscience Letters</i> 463: 108-113	IMPACT FACTOR 2.200
70.	Seemüller F, Riedel M, Obermeier M, Bauer M, <u>Adli M</u> , Mundt C, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Jäger M, Henkel V, Möller HJ (2009). The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. <i>Int J Neuropsychopharmacol</i> 12(2):181-9.	IMPACT FACTOR 4.378
71.	Berpohl F, Dalanay U, Kahnt T, Sajonz B, Heimann H, Ricken R, Stoy M, Hägele C, Schlagenhaut F, <u>Adli M</u> , Wrase J, Ströhle A, Heinz A, Bauer M (2009). A preliminary study of increased amygdala activation to positive affective stimuli in mania. <i>Bipolar Disord</i> 11: 70-75.	IMPACT FACTOR 3.959
72.	Bauer M, Glenn T, Grof P, Rasgon N, Alda M, Marsh W, Sagduyu K, Schmid R, <u>Adli M</u> , Whybrow PC (2009). Comparison of Sleep/Wake Parameters for Self-Monitoring Bipolar Disorder. <i>J Affect Disord</i> 116: 170-175.	IMPACT FACTOR 3.271
73.	Henkel V, Seemüller F, Obermeier M, <u>Adli M</u> , Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M (2009). Does early improvement triggered by antidepressants predict response/remission? - Analysis of data from a naturalistic study on a large sample of inpatients with major depression. <i>J Affect Disord</i> 115: 439-449.	IMPACT FACTOR 3.271
74.	Berghöfer A, Alda M, <u>Adli M</u> , Baethge C, Bauer M, Bschor T, Glenn T, Grof P, Müller-Oerlinghausen B, Rybakowski J, Suwalska A, Pfennig A (2008). Long-term effectiveness of lithium in bipolar disorder – a multicenter investigation of patients with typical and atypical features. <i>J Clin Psychiatry</i> 69(12):1860-8	IMPACT FACTOR 5.053
75.	Seemüller F, Riedel M, Wickelmaier F, <u>Adli M</u> , Mundt C, Marneros A, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Jäger M, Möller HJ, Henkel V (2008). Atypical symptoms in hospitalised patients with major depressive episode: frequency, clinical characteristics, and internal validity. <i>J Affect Disord</i> 108 (3): 271-278	IMPACT FACTOR 3.271
76.	Stamm TJ, <u>Adli M</u> , Kirchheiner J, Smolka MN, Kaiser R, Tremblay P, Bauer M (2008). Serotonin transporter gene and lithium augmentation response in depression. <i>Psychiatr Genetics</i> 18: 92-97	IMPACT FACTOR 2.696
77.	Bauer M, Blumentritt H, Finke R, Schlattmann P, <u>Adli M</u> , Baethge C, Bschor T, Müller-Oerlinghausen B, Berghöfer A (2007). Using ultrasonographically to determine thyroid size and prevalence of goiter in lithium-treated patients with affective disorders. <i>J Affect Disord</i> 104: 45-51	IMPACT FACTOR 3.271
78.	Knubben K, Reischies FM, <u>Adli M</u> , Schlattmann P, Bauer M, Dimeo F (2007). A randomized, controlled study on the effects of a short-term endurance	IMPACT FACTOR

	training programme in patients with major depression. <i>Br J Sports Med</i> 41(1):29-33.	2.126
79.	Grunze H, <u>Adli M</u> , Bauer M, Berger M, Bergmann A, Bräunig P, Bschor T, Falkai P, Gastpar M, Greil W, Kasper S, Krüger S, Laux G, Müller WE, Naber D, Walden J (2007). Clinical standing of valproate treatment of bipolar disorders. <i>Fortschr Neurol Psychiatr</i> 75(4): 220-235	IMPACT FACTOR 0.793
80.	Baethge C, Blumentritt H, Berghöfer A, Bschor T, Glenn T, <u>Adli M</u> , Schlattmann P, Bauer M (2005). Long-term lithium treatment and thyroid antibodies – a study of 100 patients with affective disorders and 100 normal controls. <i>J Psychiatry Neurosci</i> 30: 423-427	IMPACT FACTOR 4.123
81.	Baethge C, Baldessarini RJ, Mathiske-Schmidt K, Hennen J, Berghöfer A, Müller-Oerlinghausen B, Bschor T, <u>Adli M</u> , Bauer M (2005). Long-term combination versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. <i>J Clin Psychiatry</i> 66:174-182	IMPACT FACTOR 5.053
82.	Bschor T, Baethge C, <u>Adli M</u> , Eichmann U, Ising M, Uhr M, Modell S, Künzel H, Müller-Oerlinghausen B, Bauer M (2003). Association between response to lithium augmentation and the combined DEX/CRH test in major depressive disorder. <i>J Psychiatr Res</i> 37:135-143	IMPACT FACTOR 4.679
83.	Bschor T, Baethge C, <u>Adli M</u> , Eichmann U, Ising M, Uhr M, Müller-Oerlinghausen B, Bauer M (2003). Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. <i>Depress Anxiety</i> 17:43-48	IMPACT FACTOR 2.526
84.	Bschor T, Baethge C, <u>Adli M</u> , Lewitzka U, Eichmann U, Bauer M (2003). Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression. <i>J Psychiatry Neurosci</i> 28: 210-216	IMPACT FACTOR 4.123
85.	Bauer M, Berghöfer A, Bschor T, Baumgartner A, Kießlinger U, Hellweg R, <u>Adli M</u> , Baethge C, Müller-Oerlinghausen B (2002). Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. <i>Neuropsychopharmacology</i> 27: 620-628	IMPACT FACTOR 6.835
86.	Bauer M, Forsthoff A, Baethge C, <u>Adli M</u> , Berghöfer A, Döpfmer S, Bschor T (2002). Lithium augmentation therapy in refractory depression-update 2002. <i>Eur Arch Psychiatry Clin Neurosci</i> 253(3):132-9.	IMPACT FACTOR 2.852
87.	Bschor T, <u>Adli M</u> , Baethge C, Eichmann U, Ising M, Uhr M, Modell S, Künzel H, Müller-Oerlinghausen B, Bauer M (2002). Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. <i>Neuropsychopharmacology</i> 27: 470-478	IMPACT FACTOR 6.835
88.	Bschor T, Berghöfer A, Ströhle A, Kunz D, <u>Adli M</u> , Müller-Oerlinghausen B, Bauer M (2002). How long should the lithium augmentation strategy be maintained? A 1-year follow up of a placebo-controlled study in unipolar refractory major depression. <i>J Clin Psychopharmacol</i> 22: 427-430	IMPACT FACTOR 4.371

### **C. Case Reports:**

89.	Pilhatsch MK, Burghardt R, Wandinger KP, Bauer M, <u>Adli M</u> (2006). Augmentation with atomoxetine in treatment-resistant depression with	IMPACT FACTOR
-----	--	---------------



	psychotic features. A case report. <i>Pharmacopsychiatry</i> 39(2): 79-80.	2.402
90.	<u>Adli M</u> , Rossius W, Bauer M (1999). [Olanzapine in the treatment of depressive disorders with psychotic symptoms] Olanzapin in der Behandlung depressiver Störungen mit psychotischer Symptomatik. <i>Nervenarzt</i> 70: 68-71	IMPACT FACTOR 0.814

### C. Reviews:

91.	Ricken R, Ulrich S, Schlattmann P, <u>Adli M</u> (2017). Tranylcypramine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression. <i>Eur Neuropsychopharmacol.</i> (8):714-731.	IMPACT FACTOR 4.577
92.	Ulrich S, Ricken R, <u>Adli M</u> (2017). Tranylcypramine in mind (Part I): Review of pharmacology. <i>Eur Neuropsychopharmacol.</i> 27(8):697-713.	IMPACT FACTOR 4.577
93.	Köhler S, Cierpinsky K, Kronenberg G, <u>Adli M</u> (2016). The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. <i>J Psychopharmacol.</i> 2016 Jan; 30(1):13-22.	IMPACT FACTOR 3.898
94.	Bschor T, Bauer M, <u>Adli M</u> (2015). Comment on: Chronic and treatment resistant depression: diagnosis and stepwise therapy. [Dtsch Arztebl Int. 2014] <i>Dtsch Arztebl Int.</i> 2015 Jun 12;112(24):421-2.	IMPACT FACTOR 3,608
95.	Bschor T, Bauer M, <u>Adli M</u> (2014). Chronic and treatment resistant depression — diagnosis and stepwise therapy. <i>Dtsch Arztebl Int.</i> 111(45): 766-76	IMPACT FACTOR 3,608
96.	Krings-Ernst I, Ulrich S, Adli M (2013). Antidepressant treatment with MAO-inhibitors during general and regional anesthesia: a review and case report of spinal anesthesia for lower extremity surgery without discontinuation of tranylcypramine. <i>Int J Clin Pharmacol Ther.</i> 51(10): 763-70.	IMPACT FACTOR 1,200
97.	Köhler S, Bauer M, <u>Adli M</u> (2012). Behandlungsstrategien der therapieresistenten Depression. <i>Psychiatrie und Psychotherapie up2date</i> 6: 137-148	
98.	Rentzsch, J, Ricken R, <u>Adli M</u> (2011). Akutbehandlung der Manie. <i>Psychiatrie und Psychotherapie up2date</i> 5: 209-224	
99.	Wiethoff K, Ricken R, Keck M, Baghai T, Bauer M, Möller H, <u>Adli M</u> (2009). Das Berliner Algorithmusprojekt. <i>Nervenheilkunde</i> 4: 179-185.	IMPACT FACTOR 0.373
100.	Riedel M, Seemüller F, Wickelmaier F, Schennach-Wolff R, <u>Adli M</u> , Bauer M, Kranmüller K, Brieger P, Laux G, Bender W, Haeuser I, Zeiler J, Gaebel W, Jaeger M, Moeller H, Henkel V (2009). Häufigkeit und klinische Charakteristika von atypisch depressiven Symptomen. <i>Nervenheilkunde</i> 4: 193-199	IMPACT FACTOR 0.373
101.	Bschor T, <u>Adli M</u> (2008). Therapie depressiver Erkrankungen. Zertifizierte medizinische Fortbildung. <i>Deutsches Ärzteblatt</i> 105: 782–792	IMPACT FACTOR 1.099
102.	<u>Adli M</u> , Bauer M, Rush AJ (2006). Algorithms and collaborative care systems for depression: are they effective and why? <i>Biol Psychiatry</i> 59: 1029-1038	IMPACT FACTOR 8.672
103.	Wiethoff K, Baghai T, Heinz A, Bauer M, <u>Adli M</u> (2005). Algorithmusgestützte Behandlung depressiver Erkrankungen: Was bringen systematische Therapieansätze im klinischen Alltag? <i>Med Welt</i> 56: 332-337	
104.	Wiethoff K, Bauer M, Baghai T, Heinz A, <u>Adli M</u> (2005). Therapiealgorithmen in der Depressionsbehandlung - Das Berliner Algorithmusprojekt. <i>Nervenheilkunde</i> 24: 381-387	IMPACT FACTOR 0.373

105.	Möller HJ, <u>Adli M</u> , Laux G, Müller N, Schmitt J, unter Mitwirkung einer Expertengruppe „Kognitive Störungen bei Antidepressivabehandlung“ (2004). Kognitive und psychomotorische Effekte von Antidepressiva unter besonderer Berücksichtigung von SSRIs. <i>Psychopharmakotherapie</i> 1: 15-21	IMPACT FACTOR 0.202
106.	<u>Adli M</u> , Rush AJ, Möller H-J, Bauer M (2003). Algorithms for optimizing the treatment of depression: making the right decision at the right time. <i>Pharmacopsychiatry</i> 36 [suppl 3]: 222-229	IMPACT FACTOR 2.402
107.	Bschor T, Lewitzka U, Sasse J, <u>Adli M</u> , Koberle U, Bauer M (2003). Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms. <i>Pharmacopsychiatry</i> 36 [suppl 3]: 230-234	IMPACT FACTOR 2.402
108.	Bauer M, <u>Adli M</u> , Baethge C, Berghöfer A, Sasse J, Heinz A, Bschor T (2003). Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. <i>Can J Psychiatry</i> 48: 440-448	IMPACT FACTOR 2.828
109.	Bauer M, <u>Adli M</u> , Bschor T, Heinz A, Rasgon N, Frye M, Grunze H, Kupka R, Whybrow PC (2003). Clinical applications of levothyroxine in refractory mood disorders. <i>Clin Appr Bipol Disord</i> 2: 49-56	IMPACT FACTOR 2.531
110.	Bauer M, Forsthoff A, Baethge C, <u>Adli M</u> , Berghöfer A, Döpfmer S, Bschor T (2003). Lithium augmentation therapy in refractory depression – update 2002. <i>Eur Arch Psychiatry Clin Neurosci</i> 253: 132-139	IMPACT FACTOR 2.852
111.	Bschor T, Lewitzka U, Sasse J, <u>Adli M</u> , Koberle U & Bauer M (2003). Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms. <i>Pharmacopsychiatry</i> : 36 (Suppl 3): 230-234	IMPACT FACTOR 2.402
112.	<u>Adli M</u> , Bschor T, Canata B, Döpfmer S, Bauer M (1998). Lithium in der Behandlung der akuten Depression. <i>Fortschr Neurol Psychiat</i> 66: 435-441	IMPACT FACTOR 0.793

### **E. Comments:**

113.	Bauer M, <u>Adli M</u> , Bschor T, Döpfmer S (1999). Stellungnahme. <i>Fortschr Neurol Psychiat</i> 67: 386	IMPACT FACTOR 0.793
------	---	---------------------

### **F. Other Publications (not peer-reviewed):**

114.	<u>Adli M</u> , Berger M, Brakemeier EL, Engel L, Fingerhut J, Hehl R, Heinz A, Mayer H. J, Matussek T, Mehran N, Tolaas S, Walter H, Weiland U, Sollmann J (2016). Neurourbanistik – ein methodischer Schulterschluss zwischen Stadtplanung und Neurowissenschaften. 13(2):70-8.	
115.	Lange C, <u>Adli M</u> (2010). Residualsymptome nach akuter Depression. <i>MMW Fortschr Med</i> 152(3), 34-35.	
116.	Heimann H, Dietz F, Lange C, <u>Adli M</u> (2009). Behandlung von depressiven Episoden – Relevanz der Vollremission. <i>Neuro aktuell</i> 2: 31-33.	
117.	Bauer M, Pfennig A, Wiethoff K, Sasse J, Ricken R, Pilhatsch M, <u>Adli M</u>	

	(2006). Warum ist die Remission ein wichtiges Ziel in der Depressionsbehandlung? <i>PsychoNeuro</i> 32: 67-71	
118.	Bauer M, Köberle U, Sasse J, Gutzmann C, Neuhaus K, <u>Adli M</u> , Pfennig A, Heinz A (2005). Rezidivprophylaxe Bipolarer Erkrankungen - auf was es ankommt. <i>Schweizer Zeitschrift für Psychiatrie &amp; Neurologie</i> 1: 37-44	
119.	<u>Adli M</u> (2005). Bipolarer Alkoholiker: mit Valproinsäure zwei Fliegen mit einer Klappe schlagen? <i>Info Neurologie Psychiatrie</i> 7 [suppl1]: 12-13	
120.	Bauer M, Stamm T, Sasse J, <u>Adli M</u> (2005). Duloxetine – a novel dual acting antidepressant [Duloxetin - ein neues Antidepressivum mit dualem Wirkmechanismus]. <i>Die Psychiatrie</i> 2: 244-251	
121.	Pfennig A, <u>Adli M</u> , Bauer M (2004). Atypische Neuroleptika bei wahnhafter Depression. <i>Info Neurologie Psychiatrie</i> 6 [suppl1]: 36–37	
122.	<u>Adli M</u> (2004). Die „maskierte“ bipolare Störung: Fehldiagnose unipolare Depression vermeiden. <i>Der Neurologe &amp; Psychiater</i> 3: 38-42	
123.	Sasse J, Köberle U, Bschor T, <u>Adli M</u> , Trendelenburg M, Bauer M. (2003). Bipolare Depression: L-Thyroxin-Augmentation als Möglichkeit einer medikamentösen Behandlung. <i>PsychoNeuro</i> 29: 400-402	
124.	<u>Adli M</u> , Bauer M (2003). Wahnhafte Depression – eine vernachlässigte Sonderform. (Neuroleptika bei wahnhafter Depression). <i>Info Neurologie Psychiatrie</i> 2: 44-50	

### **G. Editor**

Bauer M, Berghöfer A, Adli M (eds.) Akute und therapieresistente Depressionen. Pharmakotherapie, Psychotherapie, Innovationen. 2., vollständig neuberarbeitete Auflage 2005 (1. Auflage 1997, 1. Nachdruck 1998). Springer Verlag, Berlin, Heidelberg, New York

### **H. Book Chapters**

Schramm E, Bauer M, Adli M, (2015). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 11. Auflage. München: Urban & Fischer S. 183-208.

Schramm E, Bauer M, Adli M, (2014). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 10. Auflage. München: Urban & Fischer S. 183-208.

Schramm E, Bauer M, Adli M, (2013). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 9. Auflage. München: Urban & Fischer S. 183-208.

Schramm E, Bauer M, Adli M, (2012). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 8. Auflage. München: Urban & Fischer

Schramm E, Bauer M, Adli M, (2011). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 7. Auflage. München: Urban & Fischer S. 165-188

Pfennig A, Adli M (2008). Antidepressiva-Hochdosisbehandlung. In: Bschor T (Hrsg.) Behandlungsmanual therapieresistente Depression. Stuttgart: Kohlhammer, S. 40-47.

Wiethoff K, Adli M (2008). Systematisierte Therapiealgorithmen (antidepressive Stufenpläne). In: Bschor T (Hrsg.) Behandlungsmanual therapieresistente Depression. Stuttgart: Kohlhammer, S. 408-418

Bschor T, Lewitzka, Adli M (2006). Lithium in non-psychiatric conditions. In: Bauer, Grof, Müller-Oerlinghausen (Hrsg.) Bauer M, Grof P, Müller-Oerlinghausen (Eds.) Lithium in Neuropsychiatry – The Comprehensive Guide. Taylor and Francis Books, Abingdon, S. 237-250

Bauer M, Pfennig A, Mavrogiorgou P, Juckel G, Adli M, Sasse J, Heinz A (2005) Perspektiven für Quetiapin in der Behandlung der unipolaren Depression. In: Möller HJ (Hrsg.) Quetiapin. Erfahrungen und Ausblicke. Schattauer GmbH, S. 131-141

Fähser NC, Wiethoff K, Adli M (2005) Therapiealgorithmen in der Langzeitpsychopharmakologie. In: Linden M, Müller WE (Hrsg.) Rehabilitationspsychopharmakologie - Psychopharmakotherapie chronifizierender und chronifizierter Erkrankungen. Köln: Deutscher Ärzteverlag, S. 43-58

Adli M, Wiethoff K (2005). Nicht-pharmakologische Behandlungsstrategien der Depression. In: Bauer M (Hrsg.) Neurobiologie und Therapie bipolarer Erkrankungen. Reihe „Uni-Med Science“. Bremen: Uni-Med, S. 103-121

Berghöfer A, Adli M, Bauer M (2005) Antidepressiva-Übersicht für die klinische Praxis. In: Bauer M, Berghöfer A, Adli M (Hrsg.). Akute und therapieresistente Depressionen. Pharmakotherapie, Psychotherapie, Innovationen. Heidelberg, Berlin, New York: Springer 2005, S. 587-600

Adli M, Wiethoff K, Baghai T, Bauer M (2005). Algorithmusgestützte Behandlung stationärer Patienten mit depressiven Erkrankungen: das Berliner Algorithmusprojekt. In: Bauer M, Berghöfer A, Adli M (Hrsg.). Akute und therapieresistente Depressionen. Pharmakotherapie, Psychotherapie, Innovationen. Heidelberg, Berlin, New York: Springer 2005, S. 477-487

Adli M, Wiethoff K (2004). Nicht-pharmakologische Behandlungsstrategien der Depression. In: Bauer M (Hrsg.) Neurobiologie und Therapie depressiver Erkrankungen. Reihe „Uni-Med Science“. Bremen: Uni-Med, S. 96-112

Adli M, Bauer (2004). M Elektrokonvulsionstherapie bei therapieresistenten Depressionen. In: T. Baghai, R. Frey, S. Kasper, H.-J. Möller (Hrsg.) Elektrokonvulsionstherapie-klinische und wissenschaftliche Aspekte. Wien: Springer, S. 366-393

Berghöfer A, Adli M, Baethge C, Bauer M, Bschor T, Müller-Oerlinghausen B, Schäfer M, Willich SN (2003). Phasenprophylaxe bipolarer Störungen. In: Deutsche Gesellschaft für Bipolare Störungen e.V. (Hrsg.), Erfurth A (Red.): Weißbuch Bipolare Störungen in Deutschland, BoD GmbH, Norderstedt, S. 131-200

Berghöfer A, Adli M, Baethge C, Bauer M, Bschor T, Müller-Oerlinghausen B, Schäfer M, Willich SN (2002). Phasenprophylaxe bipolarer Störungen. In: Deutsche Gesellschaft für Bipolare Störungen e.V. (Hrsg.), Erfurth A (Red.): Kurzfassung Weißbuch Bipolare Störungen in Deutschland, Hamburg, Conference Point, S. 67-74

Adli M, Kießlinger U, Smolka M, Neu P, Linden M, Bauer M (2001). Does algorithm-guided stepwise treatment in depression have an influence on treatment execution? In: Fromm E, ed.: Jahrbuch 2001 des Fachbereichs Humanmedizin der Freien Universität Berlin: S. 466

Adli M, Kießlinger U, Neu P, Smolka M, Linden M, Bauer M (2000). Efficacy of an algorithm-guided treatment regimen in depression compared to standard treatment as usual: The Berlin Algorithm Project. In: Fromm E, ed.: Jahrbuch 2000 des Fachbereichs Humanmedizin der Freien Universität Berlin: S. 439

Kießlinger U, Adli M, Neu P, Smolka M, Linden M, Bauer M (1999). Beschreibung medikamentöser Depressionsbehandlung. In: Jahrbuch 1999, Fachbereich Humanmedizin, Universitätsklinikum Benjamin Franklin der Freien Universität Berlin: S. 494